AI Summary Deferasirox (Exjade, Jadenu) is an oral iron chelator used for chronic iron overload when phlebotomy is not appropriate.
Medically reviewed.
Deferasirox (brand names Exjade and Jadenu) is an oral iron chelator used to treat chronic iron overload, including in selected cases of hereditary hemochromatosis where therapeutic phlebotomy is not appropriate. It works by binding excess iron in the blood and tissues and helping the body eliminate it, reducing the risk of organ damage from iron buildup. Treatment decisions should always be individualized and guided by a healthcare professional.
This page covers deferasirox's role in iron overload management — how it works, who may be eligible, benefits, side effects, and monitoring. You can also connect with a liver specialist near you for personalized guidance on whether deferasirox fits your care plan.
Liver Health AI Assistant
Ask Aimy
Aimy answers from LiverDirectory’s reviewed health information — helping patients make sense of liver-health terms, prepare for specialist visits, and explore what to look up next.
ABOUT DEFERASIROX TREATMENT
Deferasirox is a prescription medicine sold under the brand names Exjade and Jadenu. It belongs to a class of medications called iron chelators.
Deferasirox is used to treat chronic iron overload, including transfusion-dependent anemias and, in selected cases, iron overload syndromes such as hereditary hemochromatosis where therapeutic phlebotomy is not appropriate.
Unlike phlebotomy, which removes iron by drawing blood, deferasirox works by binding excess iron in the bloodstream and tissues, forming complexes that the body excretes mainly through the stool. This helps reduce iron accumulation in the liver, heart, and endocrine organs and helps prevent progression of iron-related organ damage.
Deferasirox is typically used alongside regular monitoring by your healthcare provider, including serum ferritin, kidney function, liver function, and blood counts.
WHO DEFERASIROX MAY BE SUITABLE FOR
Eligibility for deferasirox depends on your diagnosis, iron levels, and overall health. Your healthcare provider may consider deferasirox if you have chronic iron overload that cannot be managed with phlebotomy, transfusion-dependent anemia with iron accumulation, elevated ferritin levels requiring medical treatment, or if you are not a candidate for blood removal therapy and need long-term pharmacologic iron chelation.
Because deferasirox is eliminated through the body and can affect kidney and liver function in some patients, your provider will review your kidney function, liver function, and other medications before prescribing it, and will continue to monitor these throughout treatment.
Because every patient's health profile is different, there is no one-size-fits-all answer to who should take deferasirox. Treatment decisions are individualized and should be made by a qualified healthcare professional after a full assessment of your iron levels, liver condition, and treatment goals.
ELIGIBILITY OVERVIEW
Deferasirox may be considered for adults with the following conditions or treatment needs:
Before recommending deferasirox, healthcare providers evaluate several factors to determine whether it is an appropriate option, including:
HOW DEFERASIROX CAN HELP
Deferasirox binds free iron circulating in the bloodstream and in tissues. Once bound, the iron-deferasirox complex is excreted from the body mainly through the stool.
By removing excess iron systemically, deferasirox reduces the amount of iron that can accumulate in the liver, heart, and endocrine organs, helping prevent the progression of iron-related organ damage.
Unlike therapeutic phlebotomy, which lowers iron stores by removing blood, deferasirox provides systemic iron reduction without a blood-removal procedure — an option for patients who need pharmacologic chelation. Deferasirox is not used on its own; providers pair it with regular monitoring, including serum ferritin, kidney function, liver function, and blood counts, to track response and safety.
IRON REDUCTION BENEFITS
Deferasirox binds free iron in the bloodstream and tissues, forming complexes that are excreted mainly in the stool, providing systemic iron reduction.
By reducing the amount of iron circulating and stored in the body, deferasirox helps prevent iron accumulation in the liver, heart, and endocrine organs.
Lowering total body iron over time helps prevent the progression of iron-related organ damage associated with conditions like hereditary hemochromatosis and transfusion-dependent anemias.
For patients who are not candidates for blood removal therapy, deferasirox offers systemic iron reduction through a once-daily oral tablet rather than a procedure.
Deferasirox works by binding and removing excess iron from the body, helping protect organs from iron-related damage. It should only be started and monitored under the guidance of a qualified healthcare professional.
TREATMENT PROCESS
Deferasirox is available as oral tablets (Jadenu) and dispersible tablets (Exjade). Check with your pharmacist about the correct formulation and how to take your specific tablet strength.
The typical dose is 7-20 mg/kg once daily, adjusted based on ferritin levels and clinical response. Your healthcare provider determines the right dose for you and may adjust it over time.
Deferasirox is taken once daily, usually on an empty stomach or as directed by your provider. Depending on the formulation, tablets may be swallowed whole or dispersed in liquid. Always use it exactly as your healthcare provider directs.
Deferasirox is used as a long-term therapy, often continuing for months to years depending on iron burden and underlying condition. Treatment duration is guided by ongoing ferritin trends and organ iron levels.
Store deferasirox tablets at room temperature, away from moisture and heat.
Regular monitoring of serum ferritin, kidney function, liver function, and blood counts is required throughout treatment. Report any side effects or unusual symptoms to your healthcare provider.
BENEFITS AND SAFETY
Deferasirox (Exjade, Jadenu) may support people with chronic iron overload by binding excess iron in the bloodstream and tissues and helping the body eliminate it, which can reduce iron accumulation in the liver, heart, and endocrine organs. This systemic approach offers organ protection without a blood-removal procedure, making it an option for patients who are not candidates for therapeutic phlebotomy. The extent of these benefits varies from person to person, depending on iron burden, overall health, and how the body responds to therapy. Deferasirox is not a stand-alone treatment — it works best as part of a broader care plan that includes lifestyle adjustments and ongoing monitoring.
As with any medication, deferasirox may cause side effects, ranging from mild digestive symptoms to changes in kidney or liver function. Your healthcare provider will monitor serum ferritin, kidney function, liver function, and blood counts throughout treatment and assess whether deferasirox remains a suitable option for you.
BENEFITS
Deferasirox binds and removes excess iron from the body, addressing the underlying cause of organ damage in chronic iron overload.
By lowering total body iron, deferasirox helps prevent damage to the liver, heart, and endocrine organs caused by iron accumulation.
Deferasirox is a once-daily oral tablet, offering a convenient treatment option that does not require injections or infusions.
Deferasirox provides systemic iron reduction for patients who are not candidates for blood removal therapy, without the need for a procedure.
These effects are often more noticeable when starting treatment and may improve over time. Your healthcare provider will discuss the potential benefits and risks before treatment and provide ongoing support, including ferritin, kidney, and liver monitoring, to ensure safe use.
SUPPORTING YOUR RESULTS
Lifestyle changes are an important part of a comprehensive treatment plan alongside deferasirox. Patients are generally advised to avoid iron supplements unless specifically prescribed, limit vitamin C supplementation unless directed, maintain adequate hydration, and follow dietary guidance to avoid excessive iron intake.
Alcohol should be limited to reduce liver stress, since the liver is already managing the effects of iron overload.
Areas that may support treatment:
COMMON QUESTIONS
No, deferasirox (Exjade, Jadenu) is not a cure for iron overload. It is a long-term therapy that binds excess iron in the bloodstream and tissues so the body can eliminate it, mainly through the stool, which helps prevent progression of iron-related organ damage. Treatment is guided by ongoing ferritin trends and organ iron levels, and outcomes vary based on iron burden and overall health. Talk with your healthcare provider about realistic goals for your treatment plan.
Deferasirox is an oral iron chelator that binds excess iron in the blood and tissues so it can be excreted, mainly through the stool, while therapeutic phlebotomy lowers iron stores by regularly removing blood. Deferasirox is generally considered for people with chronic iron overload, such as transfusion-dependent anemia or hereditary hemochromatosis, who are not good candidates for phlebotomy or need long-term pharmacologic chelation. Your healthcare provider can help decide which approach, or combination, fits your situation.
Deferasirox treatment requires regular monitoring of serum ferritin, kidney function, liver function, and blood counts throughout therapy. These tests help your healthcare provider track how well the medication is reducing iron levels, adjust your dose (typically 7 to 20 mg/kg once daily) based on ferritin trends, and watch for changes in kidney or liver function. Monitoring frequency depends on your individual response and underlying condition. Report any new or worsening symptoms to your healthcare provider between scheduled visits.
The most common side effects of deferasirox include nausea, abdominal pain, diarrhea, and skin rash. Some patients also experience changes in kidney or liver function, which is why regular blood testing is part of treatment. These effects are often more noticeable when starting therapy and may improve over time. Contact your healthcare provider if side effects are severe, persistent, or accompanied by symptoms such as unusual fatigue, swelling, or changes in urination, so your treatment plan can be reviewed.
You should avoid iron supplements unless your healthcare provider specifically prescribes them, since deferasirox is designed to lower, not raise, iron levels. Vitamin C supplementation should also be limited unless directed, because vitamin C can increase iron absorption and work against treatment goals. Staying well hydrated and following dietary guidance to avoid excessive iron intake are also part of a comprehensive plan. Always review any supplements, herbal products, or over-the-counter medications with your healthcare provider before starting them.
Deferasirox is typically used as a long-term therapy, often continuing for months to years depending on your iron burden and underlying condition, such as hereditary hemochromatosis or a transfusion-dependent anemia. Your healthcare provider adjusts the duration based on ongoing serum ferritin trends and organ iron levels rather than a fixed timeline. Some patients may eventually reduce or stop treatment once iron levels are controlled, while others need indefinite therapy. Discuss your expected treatment length with your healthcare provider.
Medical disclaimer: LiverDirectory provides educational information and a directory of providers. It does not provide medical advice, diagnosis, or treatment. Always consult a licensed physician regarding any medical condition.
